HC Wainwright Reiterates Buy Rating for BiomX (NYSEMKT:PHGE)

BiomX (NYSEMKT:PHGE)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a report issued on Monday, Benzinga reports. They presently have a $2.00 target price on the stock. HC Wainwright’s target price would suggest a potential upside of 477.20% from the company’s current price.

BiomX Stock Performance

Shares of PHGE opened at $0.35 on Monday. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.84 and a quick ratio of 2.84. The company has a 50-day simple moving average of $0.32 and a 200 day simple moving average of $0.31. The firm has a market cap of $19.13 million, a price-to-earnings ratio of -0.65 and a beta of 1.36.

About BiomX

BiomX Inc, a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC).